What Should I Do About a Rising BCR::ABL1 PCR in CML?
At a Glance
A single rising BCR::ABL1 PCR result in CML does not automatically mean treatment failure. Keep taking your TKI, contact your hematology team, review adherence and drug interactions, and repeat testing to confirm a true trend before considering treatment changes.
In this answer
6 sections
A single unexpected rise in your BCR::ABL1 PCR result can be highly stressful, but the recommended medical response is to investigate the cause—not to panic or immediately change your medication. When a single rising result occurs, the standard approach is to contact your care team, review the lab report for technical variations, evaluate your medication habits, and repeat the test to confirm whether it is a true trend [1] [2]. You should never stop or switch your tyrosine kinase inhibitor (TKI)—the targeted therapy used to treat chronic myeloid leukemia (CML)—on your own based on one elevated result.
What to Do Now
- Keep taking your TKI exactly as prescribed: Do not stop taking it, do not take extra doses to make up for missed ones, and do not change how you take it with food unless your doctor tells you to.
- Contact your hematology team: Report the high result promptly rather than waiting passively for your next scheduled appointment.
- Gather your records: Make a list of all your current prescriptions, over-the-counter medicines, antacids, and herbal supplements to share with your team or pharmacist.
Why a Single Result Requires Confirmation
The primary test used to monitor CML is quantitative PCR (qPCR), a highly sensitive blood test that measures the level of BCR::ABL1 RNA transcripts in your blood relative to a control gene [3]. It serves as a molecular marker for your leukemia burden, but it is not a direct count of leukemia cells in your entire body.
While qPCR is a powerful tool, it has inherent technical variability [1]. This means a slight rise in your numbers might not mean your leukemia is growing; it could simply be a normal fluctuation in the testing process. Different laboratories and slight variations in testing methods can also produce different numerical values [4] [5]. Because of this variability, doctors rely on multiple measurements over time to establish a true trend, rather than making major treatment decisions based on a single, isolated measurement [2] [6].
The Step-by-Step Investigation Process
When your PCR result is unexpectedly high, your care team should take a systematic approach to figure out why:
- Review the lab report: Your doctor will check if the test was processed at your usual laboratory and ensure the results are reported on the standardized International Scale (IS), a universal measuring system used to track CML [1] [5].
- Repeat the PCR test: Drawing blood again to confirm the results is a vital step. The timing for this repeat test is individualized; it may be done very soon or within a few months, depending on the magnitude of the rise and your specific situation [2].
- Assess adherence and interactions: Taking your TKI exactly as prescribed is critical [7]. Your doctor will review if you have missed any doses. They will also look for drug interactions—such as new prescriptions, over-the-counter antacids, or supplements. Because food and drug interactions are specific to each TKI, you should not stop taking other medications or change your diet without first consulting your hematology team or pharmacist.
- Evaluate other clinical signs: Your team may review your complete blood count (CBC) (a standard test of your red, white, and platelet blood cells) and perform a physical exam to check your spleen size and ensure your overall health remains stable [3].
Understanding Milestones and Further Testing
One common milestone in CML treatment is achieving a Major Molecular Response (MMR), generally defined as a BCR::ABL1 level at or below 0.1% IS [8]. If a single test result comes back slightly above 0.1%, it does not automatically mean you have lost MMR or that your treatment is failing. However, if a repeat test confirms a sustained rise, or if your result crosses higher guideline thresholds (such as >10% at 3 months), your doctor will evaluate further [8] [9].
Depending on the size of the rise, your prior response, and your current health, your doctor might recommend:
- Mutation testing: A kinase-domain mutation test looks for specific genetic changes in the leukemia cells that can make them resistant to your current TKI [10] [11]. This test is not ordered for every small fluctuation, but rather when treatment milestones are not met or a significant trend is confirmed.
- Bone marrow examination and cytogenetics: In some cases, your doctor may need a bone marrow sample to look at your chromosomes (cytogenetics) and cells [3]. This is not automatic; it is usually reserved for cases of inadequate response, abnormal blood counts, or suspected disease progression.
When is a Medication Change Needed?
A single rising result does not automatically require a switch. The decision to change your TKI depends on the confirmed trend, response milestones, and resistance testing [9]. Furthermore, TKIs are also changed for reasons unrelated to resistance, such as significant side effects, drug interactions, pregnancy planning, or your personal treatment goals [12]. If a resistant mutation is found, your doctor will use that specific information to select a different TKI better suited to overcome the resistance [11] [13].
When to Seek Urgent Medical Advice
While a rising PCR number alone is rarely an immediate medical emergency, you should contact your doctor urgently if you experience symptoms such as unexplained fever, unusual bruising or bleeding, marked fatigue, severe or new abdominal fullness, or unexplained weight loss, as these can be signs of other health issues or disease progression.
Common questions in this guide
Does one rising BCR::ABL1 PCR result mean my CML treatment is failing?
Should I stop or change my TKI after one high PCR result?
How will my doctor confirm whether the PCR rise is real?
What might make BCR::ABL1 increase without true CML progression?
When would mutation testing or a different CML medicine be considered?
What symptoms should prompt urgent medical advice after a rising PCR result?
One line in your results can change your plan.
The decision to change a TKI depends on whether a rising BCR::ABL1 PCR result is confirmed on repeat testing. We check your results against the latest research to help you prepare for what’s next.
Related questions
Show more
Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Molecular monitoring in chronic myeloid leukemia-how low can you go?
Branford S
Hematology. American Society of Hematology. Education Program 2016; (2016(1)):156-163 doi:10.1182/asheducation-2016.1.156.
PMID: 27913475 - 2
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
Ribeiro BF, Vergílio BR, Miranda EC, et al.
Acta haematologica 2015; (134(4)):248-54 doi:10.1159/000430835.
PMID: 26159458 - 3
Molecular monitoring in CML and the prospects for treatment-free remissions.
Deininger MW
Hematology. American Society of Hematology. Education Program 2015; (2015()):257-63 doi:10.1182/asheducation-2015.1.257.
PMID: 26637731 - 4
Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia.
Jacobs K, Moerman A, Vandepoele K, et al.
International journal of laboratory hematology 2024; (46(5)):910-917 doi:10.1111/ijlh.14320.
PMID: 38840510 - 5
[Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
Larripa I, Ruiz MS, Gutiérrez M, Bianchini M
Medicina 2017; (77(1)):61-72.
PMID: 28140313 - 6
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, et al.
International journal of molecular sciences 2019; (20(9)) doi:10.3390/ijms20092226.
PMID: 31064152 - 7
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Shanmuganathan N, Hughes TP
Blood 2018; (132(20)):2125-2133 doi:10.1182/blood-2018-05-848630.
PMID: 30429156 - 8
ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
Shojaei M, Rezvani H, Azarkeivan A, Poopak B
Laboratory medicine 2021; (52(2)):158-167 doi:10.1093/labmed/lmaa052.
PMID: 32821940 - 9
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver RT, et al.
Leukemia 2020; (34(4)):966-984 doi:10.1038/s41375-020-0776-2.
PMID: 32127639 - 10
[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM, Chomel JC, Coiteux V, et al.
Bulletin du cancer 2020; (107(1)):113-128 doi:10.1016/j.bulcan.2019.05.011.
PMID: 31353136 - 11
Resistance mutations in CML and how we approach them.
Soverini S
Hematology. American Society of Hematology. Education Program 2023; (2023(1)):469-475 doi:10.1182/hematology.2023000447.
PMID: 38066920 - 12
Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
Arora R, Press RD
Leukemia & lymphoma 2017; (58(1)):8-16 doi:10.1080/10428194.2016.1190974.
PMID: 27412040 - 13
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C, Valk PJM, Blijlevens NMA, et al.
European journal of haematology 2023; (111(6)):938-945 doi:10.1111/ejh.14107.
PMID: 37731314
This page is for informational purposes only and does not constitute medical advice. Your hematology team should interpret your BCR::ABL1 trend and advise you about repeat testing or any TKI change.